{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:09:16Z","timestamp":1789826956200,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1124\/dmd.120.000215","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T22:56:27Z","timestamp":1609282587000},"page":"276-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-0431","authenticated-orcid":false,"given":"Runbin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiye","family":"Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.000215_bib7","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1021\/ac051211v","article-title":"Extraction and GC\/MS analysis of the human blood plasma metabolome","volume":"77","author":"Aa","year":"2005","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.120.000215_bib1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","article-title":"Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis","volume":"17","author":"Adorini","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.120.000215_bib2","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/dmd.120.000215_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ptr.5587","article-title":"Metabolomics study of type 2 diabetes mellitus and the AntiDiabetic effect of berberine in zucker diabetic fatty rats using Uplc-ESI-Hdms","volume":"30","author":"Dong","year":"2016","journal-title":"Phytother Res"},{"key":"10.1124\/dmd.120.000215_bib4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/nu5051544","article-title":"Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease","volume":"5","author":"Gaggini","year":"2013","journal-title":"Nutrients"},{"key":"10.1124\/dmd.120.000215_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1039\/C4MB00500G","article-title":"A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine [published correction appears in Mol Biosyst 11:664]","volume":"11","author":"Gu","year":"2015","journal-title":"Mol Biosyst"},{"key":"10.1124\/dmd.120.000215_bib6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s11306-012-0407-7","article-title":"Metabolic profile associated with glucose and cholesterol lowering effects of berberine in Sprague\u2013Dawley rats","volume":"8","author":"Jiang","year":"2012","journal-title":"Metabolomics"},{"key":"10.1124\/dmd.120.000215_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat Med"},{"key":"10.1124\/dmd.120.000215_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.taap.2011.11.006","article-title":"A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor","volume":"258","author":"Li","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib10","first-page":"897914","article-title":"Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis","volume":"2015","author":"Li","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1124\/dmd.120.000215_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12967-016-0987-5","article-title":"Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds","volume":"14","author":"Li","year":"2016","journal-title":"J Transl Med"},{"key":"10.1124\/dmd.120.000215_bib12","doi-asserted-by":"crossref","first-page":"289264","DOI":"10.1155\/2014\/289264","article-title":"Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus","volume":"2014","author":"Li","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1124\/dmd.120.000215_bib13","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1124\/dmd.110.033936","article-title":"Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats","volume":"38","author":"Liu","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000215_bib14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.120.000215_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.pharmthera.2018.06.009","article-title":"Progress and challenges of selective Farnesoid X Receptor modulation","volume":"191","author":"Massafra","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.120.000215_bib16","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jhep.2014.12.034","article-title":"Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity","volume":"62","author":"Mueller","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.120.000215_bib17","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.120.000215_bib18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1124\/dmd.120.000215_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-2003-41121","article-title":"The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption","volume":"69","author":"Pan","year":"2003","journal-title":"Planta Med"},{"key":"10.1124\/dmd.120.000215_bib20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2015.09.032","article-title":"Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies","volume":"243","author":"Pirillo","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1124\/dmd.120.000215_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"key":"10.1124\/dmd.120.000215_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.taap.2006.08.009","article-title":"Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites","volume":"217","author":"Prueksaritanont","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bbrc.2016.03.019","article-title":"Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress","volume":"472","author":"Qiang","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.120.000215_bib24","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1124\/dmd.108.021659","article-title":"Isolation and identification of urinary metabolites of berberine in rats and humans","volume":"36","author":"Qiu","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.000215_bib25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/164_2019_228","article-title":"Pharmacologic modulation of bile acid-FXR-FGF15\/FGF19 pathway for the treatment of nonalcoholic steatohepatitis","volume":"256","author":"Schumacher","year":"2019","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib26","doi-asserted-by":"crossref","first-page":"201800370R","DOI":"10.1096\/fj.201800370R","article-title":"Obesity treatment by epigallocatechin-3-gallate\u2013regulated bile acid signaling and its enriched Akkermansia muciniphila","volume":"32","author":"Sheng","year":"2018","journal-title":"FASEB J"},{"key":"10.1124\/dmd.120.000215_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.taap.2014.12.005","article-title":"Individual bile acids have differential effects on bile acid signaling in mice","volume":"283","author":"Song","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.116.106617","article-title":"Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway","volume":"91","author":"Sun","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib29","doi-asserted-by":"crossref","first-page":"e77969","DOI":"10.1371\/journal.pone.0077969","article-title":"Tissue distribution of berberine and its metabolites after oral administration in rats","volume":"8","author":"Tan","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.120.000215_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1017\/S0029665116002834","article-title":"Intestinal bile acid receptors are key regulators of glucose homeostasis","volume":"76","author":"Trabelsi","year":"2017","journal-title":"Proc Nutr Soc"},{"key":"10.1124\/dmd.120.000215_bib31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2017.02.003","article-title":"Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism","volume":"70","author":"Wang","year":"2017","journal-title":"Metabolism"},{"key":"10.1124\/dmd.120.000215_bib32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3390\/ijms17071036","article-title":"Demethyleneberberine protects against hepatic fibrosis in mice by modulating NF-\u03baB signaling","volume":"17","author":"Wang","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.120.000215_bib33","doi-asserted-by":"crossref","first-page":"e0152097","DOI":"10.1371\/journal.pone.0152097","article-title":"Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4\u03b1 miR122 pathway","volume":"11","author":"Wei","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/dmd.120.000215_bib34","doi-asserted-by":"crossref","first-page":"14.10.1","DOI":"10.1002\/cpbi.11","article-title":"Using metaboAnalyst 3.0 for comprehensive metabolomics data analysis","volume":"55","author":"Xia","year":"2016","journal-title":"Curr Protoc Bioinformatics"},{"key":"10.1124\/dmd.120.000215_bib35","doi-asserted-by":"crossref","first-page":"e16556","DOI":"10.1371\/journal.pone.0016556","article-title":"Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis","volume":"6","author":"Xia","year":"2011","journal-title":"PLoS One"},{"key":"10.1124\/dmd.120.000215_bib36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","article-title":"Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver","volume":"668","author":"Xing","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/aps.2016.120","article-title":"In vitro assessment of the glucose-lowering effects of berberrubine-9-O-\u03b2-D-glucuronide, an active metabolite of berberrubine","volume":"38","author":"Yang","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.120.000215_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.etap.2016.08.003","article-title":"High fat diet aggravates the nephrotoxicity of berberrubine by influencing on its pharmacokinetic profile","volume":"46","author":"Yang","year":"2016","journal-title":"Environ Toxicol Pharmacol"},{"key":"10.1124\/dmd.120.000215_bib39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.metabol.2008.01.013","article-title":"Efficacy of berberine in patients with type 2 diabetes mellitus","volume":"57","author":"Yin","year":"2008","journal-title":"Metabolism"},{"key":"10.1124\/dmd.120.000215_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/dmd.120.000215_bib41","doi-asserted-by":"crossref","first-page":"31441","DOI":"10.1074\/jbc.M200474200","article-title":"Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity","volume":"277","author":"Yu","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.120.000215_bib42","doi-asserted-by":"crossref","first-page":"32013","DOI":"10.18632\/oncotarget.5166","article-title":"Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1124\/dmd.120.000215_bib43","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.metabol.2009.07.029","article-title":"Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression","volume":"59","author":"Zhang","year":"2010","journal-title":"Metabolism"},{"key":"10.1124\/dmd.120.000215_bib44","doi-asserted-by":"crossref","first-page":"924851","DOI":"10.1155\/2011\/924851","article-title":"Berberine moderates glucose and lipid metabolism through multipathway mechanism","volume":"2011","author":"Zhang","year":"2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1124\/dmd.120.000215_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.120.000215_bib46","doi-asserted-by":"crossref","first-page":"e42529","DOI":"10.1371\/journal.pone.0042529","article-title":"Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1124\/dmd.120.000215_bib47","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1073\/pnas.0506982103","article-title":"Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.120.000215_bib48","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1210\/jc.2007-2404","article-title":"Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine","volume":"93","author":"Zhang","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.120.000215_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13318-013-0143-z","article-title":"An in vitro metabolic system of gut flora and the metabolism of ginsenoside Rg3 and cholic acid","volume":"39","author":"Zhao","year":"2014","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.000215_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12902-017-0165-7","article-title":"Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease","volume":"17","author":"Zhao","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"10.1124\/dmd.120.000215_bib51","first-page":"236","article-title":"Sensitive analysis and pharmacokinetic study of berberrubine using LC-MS\/MS","volume":"9","author":"Zhao","year":"2017","journal-title":"Chin Herb Med"},{"key":"10.1124\/dmd.120.000215_bib52","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.metabol.2006.10.025","article-title":"Berberine stimulates glucose transport through a mechanism distinct from insulin","volume":"56","author":"Zhou","year":"2007","journal-title":"Metabolism"},{"key":"10.1124\/dmd.120.000215_bib53","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1038\/ncomms5573","article-title":"PPAR\u03b1-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis","volume":"5","author":"Zhou","year":"2014","journal-title":"Nat Commun"},{"key":"10.1124\/dmd.120.000215_bib54","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.fitote.2013.11.010","article-title":"Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells","volume":"92","author":"Zhou","year":"2014","journal-title":"Fitoterapia"},{"key":"10.1124\/dmd.120.000215_bib55","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/aps.2016.125","article-title":"Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system","volume":"38","author":"Zou","year":"2017","journal-title":"Acta Pharmacol Sin"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624080905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.000215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:53:52Z","timestamp":1740038032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624080905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0090955624080905"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.000215","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.000215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}